Onesource Specialty Pharma Limited

BSE: 544292 NSE: ONESOURCE
Onesource Specialty Pharma Limited - chemicals in Thane, Maharashtra, India. FY 2026 financials & compliance.
CIN L74140MH2007PLC432497 Incorporated 12 June 2007 ROC Mumbai HQ Thane, Maharashtra, India
Active Listed - NSE: ONESOURCE · BSE: 544292 Public Limited Company chemicals Nifty 500
Data last updated
Market Cap
₹18,554 Cr
ONESOURCE · NSE
Share Price
₹1,618.00
-0.89% today
Revenue
₹1,422 Cr
FY 2025-26 · -1.6% YoY
EBITDA
₹294 Cr
Margin 20.7%
Net Profit
−₹64.12 Cr
FY 2025-26 · -161.1% YoY
Debt / Equity
0.17
Interest cover 803.9x
Authorised capital
₹15 Cr
Registered with MCA
Paid-up capital
₹11.47 Cr
Issued & subscribed

About Onesource Specialty Pharma Limited

Data last updated:

Onesource Specialty Pharma Limited is a public limited company based in Thane, Maharashtra, India. It operates in the chemical products segment of the chemicals sector. It was incorporated on 12 June 2007 and has been in existence for over 19 years.

Onesource Specialty Pharma is part of the Nifty 500 and BSE 500 indices. Its director Arun Kumar Pillai is #551 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L74140MH2007PLC432497. Its GSTIN is 29AABCI7084A1ZN (Karnataka). It is a listed company as per MCA records. Its shares are listed on BSE: 544292 and NSE: ONESOURCE.

The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹11.47 Cr. It was formerly known as Inbiopro Solutions Private Limited and Stelis Biopharma Private Limited. It is led by directors including Neeraj Sharma (Managing Director) and Arun Kumar Pillai.

Its last annual general meeting (AGM) was held on 30 September 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Sector 30, Thane, Maharashtra.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹1,421.59 Cr, a decline of 1.6% compared to the previous year. For the same year it recorded a net loss of ₹64.12 Cr (net margin -4.5%) and EBITDA of ₹294.29 Cr (EBITDA margin 20.7%). The net worth stands at ₹5,831.29 Cr (down 0.8% YoY). Total assets are valued at ₹7,345.79 Cr (up 7.5% YoY).

The company has about 556 employees on its provident fund (EPFO) records. Its group structure includes 1 subsidiary.

The company is associated with 4 brands: Stelis Biopharma, OneSource, Stelis Biosource and Inbiopro. As per MCA filings, the company has open charges of ₹3,471.19 Cr and satisfied charges of ₹1,558.82 Cr on record. Court records list 2 cases involving the company, including 2 filed by the company. The company has 39 deals on record (23 funding rounds, 5 secondary share transfers, 4 rights issues), with disclosed funding of ₹3,166.56 Cr; the latest was in May 2025. The company has 29 MSME Form 1 returns on record between 2019 and 2024, listing 11,729 overdue payments to 359 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website stelis.com.

Company details

CIN L74140MH2007PLC432497
Registration Number 432497
Incorporation Date 12 June 2007
ROC Mumbai
Listing Status Listed - Listed on NSE (ONESOURCE); Listed on BSE (544292)
Company Status Active
Date of Last AGM 30 September 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

Name history

Onesource Specialty Pharma has undergone 2 name changes throughout its history. The company was previously known as Inbiopro Solutions Private Limited, and Stelis Biopharma Private Limited. The current legal name is Onesource Specialty Pharma Limited.

Company NameStatus
Onesource Specialty Pharma LimitedCurrent
Inbiopro Solutions Private LimitedPrevious
Stelis Biopharma Private LimitedPrevious

CIN history

Onesource Specialty Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L74140MH2007PLC432497, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L74140MH2007PLC432497Current
U74140KA2007PLC043095Previous
U74140KA2007PTC043095Previous
Key People
Neeraj Sharma Managing Director Arun Kumar Pillai Director Colin Bond Michael Director

Recognitions & Rankings of Onesource Specialty Pharma

India's Richest People 2026 edition · 1 director · Source: Hurun India
Stock market indices
Nifty 500 BSE 500

Contact details

Onesource Specialty Pharma Limited's registered office is in Thane, Maharashtra. Its website is stelis.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    stelis.com
  • Social Media
  • Registered Address
    Unit No. 902 Cyber One, Plot No – 4 & 6 Sector 30A Vashi Navi Mumbai, Thane, Maharashtra, India – 400703
  • Industry
    Chemicals, Chemical Products, Medicinal Chemical & Botanical Products, Pharmaceuticals

To see the full contact details of Onesource Specialty Pharma Limited, buy the company report.

Comprehensive company report
Onesource Specialty Pharma Limited - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Onesource Specialty Pharma operates multiple associated brands including Stelis Biopharma, OneSource, and Stelis Biosource. Each brand links to its own profile.

BrandDescriptionWebsite
Stelis Biopharma
Offers contract development and manufacturing for drug products globally.stelis.com
OneSource
Pharmaceutical contract development and manufacturing services are offered by OneSource.onesourcecdmo.com
Stelis Biosource
End-to-end biopharmaceutical manufacturing solutions are provided by Stelis Biosource.stelisbiosource.com
Inbiopro
Biosimilars and biological therapeutics are developed in India.inbiopro.com

Business activity

The main business activity of Onesource Specialty Pharma is manufacturing. In detail, this covers manufacture of chemicals and chemical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturing20Manufacture of chemicals and chemical products

To see the full business activity and turnover split of Onesource Specialty Pharma Limited, buy the company report.

Financials of Onesource Specialty Pharma Limited

FY 2025-26 filings available

Onesource Specialty Pharma Limited reported revenue of ₹1,421.59 Cr (down 1.6% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹1,422 Cr
-1.6% YoY
EBITDA
₹294 Cr
-17.1% YoY
Profit After Tax
−₹64.12 Cr
-161.1% YoY
Net Worth
₹5,831 Cr
-0.8% YoY
Total Assets
₹7,346 Cr
+7.5% YoY
Total Debt
₹1,276 Cr
+65.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,4221,44517238.7113221.39
Revenue growth-1.6%+740.4%+344.1%-70.7%+517.7%-
EBITDA294355(230)(689)(96.66)(71.35)
EBITDA margin+20.7%+24.6%-133.6%-1780.7%-73.2%-333.6%
Profit before tax(91.97)(67.75)(391)(800)(231)(121)
Net profit(64.12)105(269)(656)(233)(121)
Net profit margin-4.5%+7.3%-156.7%-1695.5%-176.2%-564.9%
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
Balance sheet
Total assets7,3466,8349691,6522,1911,173
Net worth5,8315,8813967851,012776
Total debt1,2767725628641,154386
Cash & bank97.5730160.3379.8317077.77
Net working capital691516(179)(133)25914.20
Cash flow
Cash from operations8.52(67.85)(107)(163)(416)(118)
Cash from investing(495)(201)511(67.72)(692)(207)
Cash from financing359412(391)1181,162381
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue516449428290376327426393
Revenue growth (YoY)+37.4%+37.2%+0.5%-26.0%+12.5%+12.0%--
Other income0.953.802.134.633.045.272.896.72
EBITDA16211991.9210.2310685.6118241.36
EBITDA margin+31.3%+26.5%+21.5%+3.5%+28.3%+26.2%+42.7%+10.5%
Depreciation75.0571.7571.8369.6469.8367.8068.4968.77
Interest34.5630.8122.5138.2333.9627.4833.4145.82
Profit before tax52.8620.28(0.29)(93.01)5.74(4.40)82.81(66.51)
Tax(4.62)(4.70)(4.89)(4.31)(4.74)(4.21)(15.69)2.35
Net profit57.4824.984.60(88.70)10.48(0.19)98.50(68.86)
EPS (₹)5.012.180.40(7.74)0.91(0.02)8.59(6.31)
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Income statement
Revenue1,4051,30017238.7113221.39
Revenue growth+8.1%+655.9%+344.1%-70.7%+517.7%-
EBITDA264246(233)(645)(97.23)(72.04)
EBITDA margin+18.8%+19.0%-135.8%-1667.3%-73.6%-336.8%
Profit before tax21.20(22.14)(390)(799)(230)(121)
Net profit26.50131(269)(642)(230)(121)
Net profit margin+1.9%+10.1%-156.7%-1657.8%-174.0%-566.8%
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
Balance sheet
Total assets7,4746,8819711,6532,1941,176
Net worth5,9505,9203987871,016779
Total debt1,5049425718641,154386
Cash & bank89.9522860.2579.7616977.41
Net working capital649505(177)(132)26012.03
Cash flow
Cash from operations55.18(47.28)(109)(165)(420)(115)
Cash from investing(478)(300)506(65.68)(685)(210)
Cash from financing361417(384)1181,159381
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue514446419290375321477337
Revenue growth (YoY)+37.1%+39.1%-12.2%-13.8%+52.9%+33.7%--
Other income0.923.793.764.623.045.263.915.91
Total expenses356332344284274241241338
EBITDA15811474.705.7410279.87236(1.04)
EBITDA margin+30.8%+25.6%+17.8%+2.0%+27.1%+24.9%+49.5%-0.3%
Depreciation39.0436.1834.7434.5734.2133.2833.5933.98
Interest34.1830.5222.2537.9933.3127.0332.3943.92
Profit before tax86.2051.2221.47(62.20)37.1024.82174(73.03)
Tax0.000.000.000.000.000.000.000.00

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 10 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue516449428290376327426393
Revenue growth (YoY)+37.4%+37.2%+0.5%-26.0%+12.5%+12.0%--
Other income0.953.802.134.633.045.272.896.72
EBITDA16211991.9210.2310685.6118241.36
EBITDA margin+31.3%+26.5%+21.5%+3.5%+28.3%+26.2%+42.7%+10.5%
Depreciation75.0571.7571.8369.6469.8367.8068.4968.77
Interest34.5630.8122.5138.2333.9627.4833.4145.82
Profit before tax52.8620.28(0.29)(93.01)5.74(4.40)82.81(66.51)
Tax(4.62)(4.70)(4.89)(4.31)(4.74)(4.21)(15.69)2.35
Net profit57.4824.984.60(88.70)10.48(0.19)98.50(68.86)
EPS (₹)5.012.180.40(7.74)0.91(0.02)8.59(6.31)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,4221,44517238.7113221.39
Revenue growth-1.6%+740.4%+344.1%-70.7%+517.7%-
Other income15.0217.474.232.693.771.01
Total expenses1,1271,09040272822992.74
Employee cost0.0021579.3672.8060.9935.60
EBITDA294355(230)(689)(96.66)(71.35)
EBITDA margin+20.7%+24.6%-133.6%-1780.7%-73.2%-333.6%
Depreciation27927476.2965.6870.3534.40
Interest12216689.4547.5568.0315.82
Profit before tax(91.97)(67.75)(391)(800)(231)(121)
Tax(18.16)(49.79)0.000.00(0.11)0.27
Net profit(64.12)105(269)(656)(233)(121)
Net profit margin-4.5%+7.3%-156.7%-1695.5%-176.2%-564.9%
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.4611.444.014.013.041.54
Reserves & surplus5,8195,8693927811,009774
Shareholders' funds (net worth)5,8315,8813967851,012776
Minority interest0.000.000.000.000.000.00
Secured loans1,140658137433597309
Unsecured loans13611442543155776.59
Total debt1,2767725628641,154386
Total liabilities7,3466,8349691,6522,1911,173
Assets
Gross block6,7996,6441,1391,6331,391718
Net block6,0176,1188631,3611,231633
Capital work in progress529218188334490431
Investments15.6815.7919.584.500.000.00
Inventories5332651281392754.89
Sundry debtors69041755.243.8223.642.22
Cash & bank balances97.5730160.3379.8317077.77
Loans & advances19420233.797.1042.2413.83
Total current assets1,5151,18427823051198.71
Total current liabilities82466845736325284.51
Net working capital691516(179)(133)25914.20
Total assets7,3466,8349691,6522,1911,173
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash16522.269.4712267.2911.28
Net cash from operating activities8.52(67.85)(107)(163)(416)(118)
Net cash from investing activities(495)(201)511(67.72)(692)(207)
Net cash from financing activities359412(391)1181,162381
Net change in cash(127)14312.79(112)54.4756.01
Closing cash97.5730160.3379.8317077.77
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth-1.6%+740.4%+344.1%-70.7%+517.7%-
EBITDA growth-17.1%+254.6%+66.7%-613.1%-35.5%-
PBT growth-35.8%+82.7%+51.1%-245.9%-91.8%+9997.0%
Net income growth-161.1%+139.0%+59.0%-181.9%-92.7%-
Revenue CAGR (3Y)+232.4%+122.0%+100.3%---
EBITDA CAGR (3Y)--+47.7%---
Profitability & leverage
Net income margin-5.2%-1.2%-227.5%-2066.2%-175.0%-564.9%
Return on capital employed0.0%0.0%0.0%0.0%0.0%0.0%
Return on net worth0.0%0.0%0.0%0.0%0.0%0.0%
Debt / equity0.170.211.211.120.860.72
Long-term debt / equity0.070.080.530.530.510.56
Interest cover803.88205.08-29.24-6.30-40.73-14.96
Efficiency & per share
Fixed asset turnover0.210.370.120.030.130.04
Inventory turnover3.567.351.290.190.948.75
Debtors turnover2.576.125.822.8210.2219.18
EPS (₹)(6.44)(1.57)(97.55)(199.46)(76.14)(783.08)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)508.70513.9098.68195.87333.495,029.28
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue514446419290375321477337
Revenue growth (YoY)+37.1%+39.1%-12.2%-13.8%+52.9%+33.7%--
Other income0.923.793.764.623.045.263.915.91
Total expenses356332344284274241241338
EBITDA15811474.705.7410279.87236(1.04)
EBITDA margin+30.8%+25.6%+17.8%+2.0%+27.1%+24.9%+49.5%-0.3%
Depreciation39.0436.1834.7434.5734.2133.2833.5933.98
Interest34.1830.5222.2537.9933.3127.0332.3943.92
Profit before tax86.2051.2221.47(62.20)37.1024.82174(73.03)
Tax0.000.000.000.000.000.000.000.00
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Revenue1,4051,30017238.7113221.39
Revenue growth+8.1%+655.9%+344.1%-70.7%+517.7%-
Other income15.0127.658.752.705.861.01
Total expenses1,1421,05340568422993.43
Employee cost24021579.3672.8056.9731.22
EBITDA264246(233)(645)(97.23)(72.04)
EBITDA margin+18.8%+19.0%-135.8%-1667.3%-73.6%-336.8%
Depreciation13713576.2910970.3534.40
Interest12116289.4247.5568.0215.80
Profit before tax21.20(22.14)(390)(799)(230)(121)
Tax0.00(41.46)0.000.000.000.00
Net profit26.50131(269)(642)(230)(121)
Net profit margin+1.9%+10.1%-156.7%-1657.8%-174.0%-566.8%
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Equity & liabilities
Share capital11.4611.444.014.013.911.54
Reserves & surplus5,9385,9093947831,012777
Shareholders' funds (net worth)5,9505,9203987871,016779
Secured loans1,1406581373831,154309
Unsecured loans3642854344810.0076.59
Total debt1,5049425718641,154386
Total liabilities7,4746,8819711,6532,1941,176
Assets
Gross block3,6973,5871,1391,6331,392718
Net block3,1983,2008631,3611,231633
Capital work in progress469206188334440382
Investments2,9312,84819.704.5151.6753.19
Inventories5332601281392634.89
Sundry debtors73544255.413.7436.602.24
Cash & bank balances89.9522860.2579.7616977.41
Loans & advances18719233.747.0543.0713.83
Total current assets1,5461,12227823051298.37
Total current liabilities89761645536125186.34
Net working capital649505(177)(132)26012.03
Total assets7,4746,8819711,6532,1941,176
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Opening cash92.0922.199.4112166.9211.17
Net cash from operating activities55.18(47.28)(109)(165)(420)(115)
Net cash from investing activities(478)(300)506(65.68)(685)(210)
Net cash from financing activities361417(384)1181,159381
Net change in cash(61.37)69.9012.78(112)54.5555.76
Closing cash89.9522860.2579.7616977.41
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21
Growth
Sales growth+8.1%+655.9%+344.1%-70.7%+517.7%-
EBITDA growth+7.0%+205.5%+63.8%-563.8%-35.0%-
PBT growth+9998.0%+94.3%+51.2%-247.8%-89.5%+9997.0%
Net income growth-79.7%+148.5%+58.0%-179.2%-89.6%-
Revenue CAGR (3Y)+231.1%+114.3%+100.3%---
EBITDA CAGR (3Y)--+48.0%---
Profitability & leverage
Net income margin+1.5%+1.5%-227.1%-2064.4%-173.9%-566.8%
Return on capital employed+1.6%+5.2%0.0%0.0%0.0%0.0%
Return on net worth+0.3%+3.2%0.0%0.0%0.0%0.0%
Debt / equity0.210.241.211.120.860.72
Long-term debt / equity0.100.100.540.530.510.56
Interest cover95.12144.51-28.87-6.30-40.59-14.84
Efficiency & per share
Fixed asset turnover0.390.550.120.030.130.04
Inventory turnover3.546.691.290.190.998.75
Debtors turnover2.395.235.811.926.8019.01
EPS (₹)1.851.69(97.36)(1,992.80)(58.76)(785.74)
Dividend per share (₹)0.000.000.000.000.000.00
Book value per share (₹)519.07517.3699.191,961.88259.755,045.70

To see the full year-wise statements and ratios of Onesource Specialty Pharma Limited, buy the company report.

Board of directors of Onesource Specialty Pharma Limited

Onesource Specialty Pharma has 8 current directors and 34 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Arun Kumar Pillai
Also directs: Chayadeep Ventures LLP, Agnus Capital LLP, Karuna Group LLP and 3 more
Director07 Apr 20215 Years 7 MonthsCurrent
Colin Bond MichaelDirector23 Jun 20251 Years 4 MonthsCurrent
Debarati SenDirector27 Feb 20251 Years 8 MonthsCurrent
Claudio Dr Albrecht
Also directs: Dr.Reddy's Laboratories Ltd
Director27 Feb 20251 Years 8 MonthsCurrent
Vijay Paul KarwalDirector27 Feb 20251 Years 8 MonthsCurrent
Bharat Dhirajlal Shah
Also directs: Sunaru LLP, Salisbury Investments Private Limited, Credila Financial Services Limited
Director26 Jul 20242 Years 3 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Auditor

Onesource Specialty Pharma Limited is audited by Deloitte Haskins & Sells for the financial year 2025.

Auditor firmFinancial yearFirm registration number
Deloitte Haskins & SellsFY 2025008072S

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 30.50%, foreign institutional investors hold 19.20%, domestic institutional investors hold 23.40% and retail and other public shareholders hold 27.00%.

Promoters: 30.50%DII (Domestic Institutional): 23.40%FII (Foreign Institutional): 19.20%Retail & Others: 27.00%
Sep 2026
QUARTER
30.50% Promoters
23.40% DII (Domestic Institutional)
19.20% FII (Foreign Institutional)
27.00% Retail & Others
Promoter holding - history
Now 30.50% · Sep 2026High 30.50% · Jun 2026Low 29.80% · Dec 2025
28%29%30%31%32%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 29.80%Mar 2026: 29.90%Jun 2026: 30.50%Sep 2026: 30.50%30.50%29.80%30.50%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters30.50%30.50%29.90%29.80%
Public69.50%69.50%70.10%70.20%

Charges & borrowings

Open charges
₹3,471.19 Cr
Satisfied charges
₹1,558.82 Cr
Breakdown by lending institutions
Others₹2,881.19 Cr
Yes Bank Limited₹275.00 Cr
Hdfc Bank Limited₹190.00 Cr
Standard Chartered Bank₹125.00 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
07 Aug 2026101376409Others₹202.1 CrOpen
31 Jul 2026101387700Hdfc Bank Limited₹100 CrOpen
12 Jun 2026101312776Others₹310.58 CrOpen
27 Dec 2025101218579Yes Bank Limited₹100 CrOpen
15 Dec 2025101213461Others₹100 CrOpen

To see the full charge records of Onesource Specialty Pharma Limited, buy the company report.

Total charge records: 34 View all charges

Deals & funding

Onesource Specialty Pharma Limited has 39 deals on record (23 funding rounds, 5 secondary share transfers, 4 rights issues), with disclosed funding of ₹3,166.56 Cr; the latest was in May 2025.

Total deals
39
Funding rounds
23
Secondary share transfers
5
Rights issues
4
Acquisitions
3
Disclosed funding
₹3,166.56 Cr

Deals on record (5 of 39)

WhenDealAmountParties
Oct 2024Funding round₹801 CrInvestors: White Oak Capital Management, Param Capital, Enam Holdings, an individual
Jul 2023Acquisition₹702 CrBuyer: Syngene International Limited
Seller: Onesource Specialty Pharma Limited
May 2023Debt financing₹212.8 CrInvestors: Good Day Enterprises LLP, Nova Global Opportunities Fund PCC - Touchstone, Shyam Sel and Power Limited
Aug 2021Funding round₹510.57 CrInvestors: Agnus Capital, Tenshi Life Sciences Private Limited , Arco Lab Private Limited
May 2020Funding round₹283.25 CrInvestors: Strides Pharma Science Limited , GMS Pharma (Singapore) Pte Limited

To see the full deal history of Onesource Specialty Pharma Limited, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

Credit ratings & regulatory alerts

Onesource Specialty Pharma Limited was last rated by Icra on 14 Jun 2021.

Rating agencyRated onRating
Icra14 Jun 2021

To see the full credit ratings and regulatory alerts of Onesource Specialty Pharma Limited, buy the company report.

MSME payment delays

Onesource Specialty Pharma Limited has 29 MSME Form 1 returns on record between 2019 and 2024, listing 11,729 overdue payments to 359 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 359)

SupplierAmount dueDue sinceReported on
an individual supplier
Helix Scientific
Akshara Designs Private Limited
Profisolutions Private Limited
Transaction Square LLP

To see the full MSME payment records of Onesource Specialty Pharma Limited, buy the company report.

Individuals and sole proprietors among the suppliers are not named.

Group structure & subsidiaries

Onesource Specialty Pharma has 1 subsidiary company. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.

1
Subsidiary companies
Key subsidiaries
Company NameCINShares held
Biolexis Private LimitedU24239KA2022PTC156696

To see the full group structure of Onesource Specialty Pharma Limited, buy the company report.

Employees & EPFO

Onesource Specialty Pharma Limited has a workforce of 556 employees on its EPFO records as of Mar 10, 2025, across 1 active EPFO establishment.

Employee count
556
Active EPFO establishments
1
Employee growth
8.17%

GST

Onesource Specialty Pharma has 1 GST registration: 1 active.

Total GSTINs
1
Active
1
GSTINStateStatusRegistered on
29AABCI7084A1ZNKarnatakaActive01 Jul 2017

To see the full GST registrations and return filing status of Onesource Specialty Pharma Limited, buy the company report.

Recent activity

Onesource Specialty Pharma Limited has 70 board changes on record since 2007: 40 appointments and 30 cessations. The latest: Colin Bond Michael was appointed as Director on 23 Jun 2025.

AGM
Onesource Specialty Pharma Limited last Annual general meeting of members was held on 30 Sep 2026 as per latest MCA records.
Charges
A charge registered on 28 Jan 2026 via Charge ID 101242244 with Others was fully satisfied on 10 Sep 2026.
Charges
A charge with Others of Rs. 125.00 Cr registered on 04 Mar 2025 with Charge ID 101063095 was modified on 31 Aug 2026.
Charges
A charge with Others amounted to Rs. 202.10 Cr with Charge ID 101376409 was registered on 07 Aug 2026.
Charges
A charge with Hdfc Bank Limited amounted to Rs. 100.00 Cr with Charge ID 101387700 was registered on 31 Jul 2026.
Charges
A charge registered on 13 May 2021 via Charge ID 100446574 with Idbi Trusteeship Services Limited was fully satisfied on 28 Jul 2026.
Charges
A charge with Hdfc Bank Limited of Rs. 90.00 Cr registered on 28 Feb 2025 with Charge ID 101080678 was modified on 23 Jul 2026.
Charges
A charge with Others amounted to Rs. 310.58 Cr with Charge ID 101312776 was registered on 12 Jun 2026.
Charges
A charge with Others of Rs. 1,342.49 Cr registered on 13 Nov 2025 with Charge ID 101193627 was modified on 21 May 2026.
Charges
A charge registered on 27 Feb 2024 via Charge ID 100914818 with Others was fully satisfied on 03 May 2026.
Filing
Onesource Specialty Pharma Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Mumbai Ii.
Charges
A charge with Others amounted to Rs. 75.00 Cr with Charge ID 101242244 was registered on 28 Jan 2026.

121 earlier events are in the company report.

News

ONESOURCE: Gets USFDA EIR With VAI Status, Finishing Inspection At Bengaluru's Sterile Product Division Facility.
30 Oct 2026 · Exchange Update
ONESOURCE: Q2 SL NET PROFIT 862M RUPEES VS 371M (YOY)
27 Oct 2026 · Exchange Update
ONESOURCE: Q2 REVENUE 5.14B RUPEES VS 3.76B (YOY)
27 Oct 2026 · Exchange Update
ONESOURCE: Q2 EBITDA 1.58B RUPEES VS 1B (YOY); Q2 EBITDA MARGIN 30.8% VS 27.07% (YOY)
27 Oct 2026 · Exchange Update
Onesource Specialty: Expects Semaglutide Approvals In Brazil And Turkey Within The Next 2 Quarters.
27 Oct 2026 · Exchange Update

Frequently asked questions

Onesource Specialty Pharma is an active public limited company based in Thane, Maharashtra, India. The company works in chemical products, within the chemicals industry. It was incorporated on 12 June 2007 (19+ years old) and is registered under CIN L74140MH2007PLC432497. Listed on BSE: 544292 and NSE: ONESOURCE.

Onesource Specialty Pharma reported revenue of ₹1,421.59 Cr for FY 2025-26 (down 1.6% YoY) based on consolidated financials.

Onesource Specialty Pharma has 8 current directors:

The latest financial statements of Onesource Specialty Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 30 September 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Onesource Specialty Pharma is 29AABCI7084A1ZN, registered in Karnataka.

The CIN (Corporate Identification Number) of Onesource Specialty Pharma is L74140MH2007PLC432497. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Onesource Specialty Pharma is a listed company as per MCA records. Its shares are listed on both BSE (code: 544292) and NSE (symbol: ONESOURCE).

Onesource Specialty Pharma has 2 court cases on record: 2 filed by the company.

Onesource Specialty Pharma was incorporated on 12 June 2007, making it 19+ years old. It is registered with the Registrar of Companies, Mumbai.

Onesource Specialty Pharma has 39 deals on record (23 funding rounds, 5 secondary share transfers, 4 rights issues), with disclosed funding of ₹3,166.56 Cr; the latest was in May 2025.

Colin Bond Michael was appointed as Director on 23 Jun 2025. Bhushan Sudhir Bopardikar ceased to be Director on 27 Feb 2025. Claudio Dr Albrecht was appointed as Director on 27 Feb 2025. Onesource Specialty Pharma has 70 board changes on record in total.